...well IDRA had a nice run this afternoon on IND news. Maybe there is more to a retired air bus driver than one thought earlier.
...you should write for Motley Fool. They make a statement "Geron announced that five of the 22 patients in the Mayo Clinic study achieved partial or complete remissions, while 41% responded to the therapy" then spin it like it was a liability. Does ruxolitintib exhibit such results?
I really think a partnership or buyout will happen bfr FDA phase 3 trials are launched.
on the flip side of course, those same people as we saw that were shorting in the last couple days can add to the upside movement when they are forced to cover. There seems a lot underfoot here that we nor the market are aware yet so the flip side can happen just as fast. Down 20% in 2 days up 50% in 5
...we could get into a whole discussion on many promising treatments that big pharma or the FDA won't back if they can't see profit in it. Unfortunately helping those less fortunate isn't Wall Street's mantra. We can't even get comprehensive universal healthcare in this nation as it's controlled by private corporate interests. Some recent gene therapy looks very promising but will require alot of further investments. Congress chooses to spend trillions on a bigger watch dog than a better health care system. One only has to drive around Washington to see the huge network of security related development that has taken place lately. 16 separate divisions of intelligence now running under the DNI, yet no one is saying enough is enough. They would be quickly muzzled. Most Americans are oblivious of this growing bureaucratic budget cancer eating away at our core. No longer do we put our faith in God but rather drones and weapons.
I digress...my prayers go out to your loved one.
3 Black Crows; how to play
Step 1 – Look for 3 BLACK CROWS resting on Minor Price Support, and/or a rising Major Moving Average (10 MA, 20 MA, or 50 MA). Ideally you want to find a series of 3 red candlesticks GERN
Step 2 – Pull up a 15 min. chart of the stock
Step 3 – Monitor the stock’s trading during the last 30 minutes before the close today, and enter only if the stock is closing strong near it’s high price of the day. You will reduce your risk by entering only if the range of the day (high price minus low play price) is narrow. This way, when you set your protective stop at the day’s low, you will only take a small loss if the stock should reverse
Step 4 – Observe the daily chart after the market has closed today. The stock has now formed a BULLISH HARAMI on the daily chart, but you were able to spot the setup on the previous day and enter before the rest of the herd! On the next day, observe where the stock opens. If the stock opens relatively near to the opening price (say within 5/8th), place the initial protective stop 1/8th below the low of the previous day’s candlestick. Exit the stock immediately if the stock breaks below this price. If the stock gaps up, proceed to Step 6. If the stock gaps down, proceed to Step 8.
Step 5 – Monitor the stock as it continues to rally upward. Look for areas of support (either minor price support or base price support) on the 15 minute chart, and re-adjust your protective stop price to 1/8th under these levels of support. This will protect your profits, and/or minimize your losses if the stock should turn against you....
Step 6 -ah nevermind.... just go and buy some T-bills
well they had a nice run up to last months high of $70+ so I'd expect profit taking and tax sell off issues at work. They still have TSRX's pipeline with some interesting antibiotic seaweed data stuff yet to come.
The market generally has taken a rest. I'm sure GERN would have responded much better to trial study data results earlier this week had it been a green market the last two days. This is where shorts can do a great deal of damage to the market's overall sentiment. Scare off what little retail is left and the big hedge funds will be trading amongst themselves. Many are on the sidelines not convinced of the weak recovery in place.
50DMA is $4.50 It showed up as 3 black crows last night on candles which if it bounces off the 50 means a strong bullish BUY indicator. If you get stopped out better to wait it out and see. The data leak last Thursday stole GERN's thunder IMO and the market never responded to the stellar breakthrough data on Imetelstat on the Mayo pilot study.
In light of the recent breakthrough presentation of post phase 1 data for imetelstat @ the ASH conference on Monday it got me back to thinking of when TSRX presented data for their early studies on their key pipeline drug. TSRX's SP following the Biotech conference and a presentation at ECCMID in April 2013 was followed by a sharp rise and an eventual buyout by Cubist(one of 3 contenders I might add) by mid summer.
GERN's earlier findings followed a report that was detailed at the18th Annual Congress of the European Hematology Association in 2013 showing a 100% hematologic response rate in 18 patients with essential thrombocytopenia treated with imetelstat, including 16 complete responses. Those results added to a favorable report at last year's 2012 ASH Annual Meeting involving fewer patients and a shorter duration of follow-up. Those studies showed that imetelstat reduces platelet counts, and laboratory studies demonstrated selective inhibition of proliferation of malignant progenitors and good distribution of the drug to bone marrow obtained from patients with ET. Outcomes of these preceding studies led to the recent pilot study at the Mayo Clinic to evaluate imetelstat in myeloid malignancies. The steller data on this recent pilot study was released(leaked earlier) during this past Monday's 2013 DEC. ASH Annual Meeting.
The similarities are similar in timing of both company's actions wrt a buyout paradigm. GERN has the goods, now BIG pharma can show us the money.
...the extra terrestrials may have it under wrap. Soon to be unveiled at a hanger near you.
Ret said the same thing about Scarlett's stewardship of Tara after Atlanta was burnt to the ground. She raised it up from the ASH